Literature DB >> 879029

Veterans Administration Cooperative Study of Surgery for Coronary Arterial Occlusive Disease. III. Methods and baseline characteristics, including experience with medical treatment. By the Veterans Administration Cooperative Group for the Study of Surgery for Coronary Arterial Occlusive Disease.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 879029

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  8 in total

1.  CORONARY ARTERY BYPASS-ARE MULTICENTER COOPERATIVE RANDOM STUDIES MISLEADING?

Authors:  Robert J. Hall; Efrain Garcia; Virendra S. Mathur; Carlos M. De Castro
Journal:  Cardiovasc Dis       Date:  1978-03

2.  UPDATE ON SURGERY FOR CORONARY ARTERY OCCLUSIVE DISEASE.

Authors:  William E. Bloomer; Myrvin Ellestad
Journal:  Cardiovasc Dis       Date:  1979-06

3.  Results of a randomized study of medical and surgical management of angina pectoris.

Authors:  T Takaro
Journal:  World J Surg       Date:  1978-11       Impact factor: 3.352

Review 4.  The practical implications of the coronary artery surgery trials.

Authors:  D G Julian
Journal:  Br Heart J       Date:  1985-10

5.  Factors influencing late survival after coronary bypass surgery.

Authors:  G M Lawrie; G C Morris
Journal:  Ann Surg       Date:  1978-06       Impact factor: 12.969

6.  Monitoring the diffusion of a technology: coronary artery bypass surgery in Ontario.

Authors:  G M Anderson; J Lomas
Journal:  Am J Public Health       Date:  1988-03       Impact factor: 9.308

7.  Coronary artery surgery: indications and recent experience.

Authors:  P S Robinson; D J Coltart; B S Jenkins; M M Webb-Peploe; M V Braimbridge; B T Williams
Journal:  Postgrad Med J       Date:  1978-10       Impact factor: 2.401

Review 8.  Functional Angioplasty: Definitions, Historical Overview, and Future Perspectives.

Authors:  Hanbit Park; Do-Yoon Kang; Cheol Whan Lee
Journal:  Korean Circ J       Date:  2022-01       Impact factor: 3.243

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.